Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F W Cremer

Showing results (1-10 of 18) with videos related to

Pageof 2
Sort By:
British Journal of Haematology|January 14, 1999
Leukapheresis cells of patients with multiple myeloma collected after mobilization with chemotherapy and G-CSF do not bear Kaposi's sarcoma associated herpesvirus DNAF Bellos, F W Cremer, E Ehrbrecht, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 1, 1997
A quantitative PCR assay for the detection of low amounts of malignant cells in multiple myelomaF W Cremer, K Kiel, M Wallmeier, et al.
Der Internist|September 12, 2003
[Multiple myeloma. Diagnosis and therapy]H Goldschmidt, F W Cremer, T M Möhler, et al.
Bone Marrow Transplantation|December 26, 2001
Molecular monitoring of the tumor load predicts progressive disease in patients with multiple myeloma after high-dose therapy with autologous peripheral blood stem cell transplantationE Lipinski, F W Cremer, A D Ho, et al.
Experimental Hematology|September 5, 1998
Leukapheresis products in multiple myeloma: lower tumor load after mobilization with cyclophosphamide plus granulocyte colony-stimulating factor (G-CSF) compared with G-CSF aloneF W Cremer, K Kiel, M Wallmeier, et al.
Bone Marrow Transplantation|June 30, 1998
First and second apheresis in patients with multiple myeloma: no differences in tumor load and hematopoietic stem cell yieldK Kiel, F W Cremer, E Ehrbrecht, et al.
Leukemia|January 22, 1998
A rationale for positive selection of peripheral blood stem cells in multiple myeloma: highly purified CD34+ cell fractions of leukapheresis products do not contain malignant cellsF W Cremer, K Kiel, C Sucker, et al.
Bone Marrow Transplantation|November 18, 2000
Evaluation of the kinetics of the bone marrow tumor load in the course of sequential high-dose therapy assessed by quantitative PCR as a predictive parameter in patients with multiple myelomaF W Cremer, E Ehrbrecht, K Kiel, et al.
British Journal of Haematology|August 25, 1999
Clonotypic CD20+ and CD19+ B cells in peripheral blood of patients with multiple myeloma post high-dose therapy and peripheral blood stem cell transplantationC Rottenburger, K Kiel, T Bösing, et al.
Bone Marrow Transplantation|June 18, 1999
Analysis of circulating tumor cells in patients with multiple myeloma during the course of high-dose therapy with peripheral blood stem cell transplantationK Kiel, F W Cremer, C Rottenburger, et al.
Pageof 2

Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
British Journal of Haematology|January 14, 1999
Leukapheresis cells of patients with multiple myeloma collected after mobilization with chemotherapy and G-CSF do not bear Kaposi's sarcoma associated herpesvirus DNAF Bellos, F W Cremer, E Ehrbrecht, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 1, 1997
A quantitative PCR assay for the detection of low amounts of malignant cells in multiple myelomaF W Cremer, K Kiel, M Wallmeier, et al.
Der Internist|September 12, 2003
[Multiple myeloma. Diagnosis and therapy]H Goldschmidt, F W Cremer, T M Möhler, et al.
Bone Marrow Transplantation|December 26, 2001
Molecular monitoring of the tumor load predicts progressive disease in patients with multiple myeloma after high-dose therapy with autologous peripheral blood stem cell transplantationE Lipinski, F W Cremer, A D Ho, et al.
Experimental Hematology|September 5, 1998
Leukapheresis products in multiple myeloma: lower tumor load after mobilization with cyclophosphamide plus granulocyte colony-stimulating factor (G-CSF) compared with G-CSF aloneF W Cremer, K Kiel, M Wallmeier, et al.
Bone Marrow Transplantation|June 30, 1998
First and second apheresis in patients with multiple myeloma: no differences in tumor load and hematopoietic stem cell yieldK Kiel, F W Cremer, E Ehrbrecht, et al.
Leukemia|January 22, 1998
A rationale for positive selection of peripheral blood stem cells in multiple myeloma: highly purified CD34+ cell fractions of leukapheresis products do not contain malignant cellsF W Cremer, K Kiel, C Sucker, et al.
Bone Marrow Transplantation|November 18, 2000
Evaluation of the kinetics of the bone marrow tumor load in the course of sequential high-dose therapy assessed by quantitative PCR as a predictive parameter in patients with multiple myelomaF W Cremer, E Ehrbrecht, K Kiel, et al.
British Journal of Haematology|August 25, 1999
Clonotypic CD20+ and CD19+ B cells in peripheral blood of patients with multiple myeloma post high-dose therapy and peripheral blood stem cell transplantationC Rottenburger, K Kiel, T Bösing, et al.
Bone Marrow Transplantation|June 18, 1999
Analysis of circulating tumor cells in patients with multiple myeloma during the course of high-dose therapy with peripheral blood stem cell transplantationK Kiel, F W Cremer, C Rottenburger, et al.
Pageof 2